Literature DB >> 21892031

Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy.

Maria Lucia Calcagni1, Guido Galli, Alessandro Giordano, Silvia Taralli, Carmelo Anile, Andreas Niesen, Richard Paul Baum.   

Abstract

PURPOSE: (1) To investigate the diagnostic value of some O-(2-[F]fluoroethyl)-L-tyrosine (F-18 FET) indices derived from the dynamic acquisition to differentiate low-grade gliomas from high-grade; (2) to analyze the course of tumor time-activity curves (TACs); and (3) to calculate the individual probability of a high-grade glioma using the logistic regression.
METHODS: Seventeen low-grade (WHO I-II) and 15 high-grade (WHO III-IV) gliomas were studied with dynamic F-18 FET PET. Regions of interests were drawn over the tumor and contralateral brain, and TACs were analyzed. We considered early standardized uptake value (SUV), middle SUV, late SUV, early-to-middle SUV tumor ratio, early-to-late SUV tumor ratio; time to peak (Tpeak), in minutes, from the beginning of the dynamic acquisition up to the maximum SUV of the tumor; and SoD (sum of the frame-to-frame differences). To assess the individual probability of high-grade, logistic regression was also used.
RESULTS: High-grade gliomas showed significantly (P < 0.0001) higher values when compared with low-grade gliomas in early SUV, early-to-middle ratio, early-to-late ratio, Tpeak, and SoD. For the grading of gliomas, the best indices were early-to-middle ratio and Tpeak providing a diagnostic accuracy of 94%. TACs analysis provided an 87% diagnostic accuracy. For individual high-grade diagnosis, the logistic regression provided 93% sensitivity, 100% specificity, and 97% accuracy.
CONCLUSION: Early-to-middle SUV tumor ratio and Tpeak were the best indices for assessing the grading of gliomas. Since early-to-middle ratio derives from the first 35 minutes of the dynamic acquisition, the PET study could last half an hour instead of 1 hour. By logistic regression, it is possible to assess the individual probability of high-grade, useful for prognosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21892031     DOI: 10.1097/RLU.0b013e3182291b40

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  35 in total

1.  Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans.

Authors:  Nathalie L Albert; Isabel Winkelmann; Bogdana Suchorska; Vera Wenter; Christine Schmid-Tannwald; Erik Mille; Andrei Todica; Matthias Brendel; Jörg-Christian Tonn; Peter Bartenstein; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-15       Impact factor: 9.236

2.  Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas.

Authors:  Manuel Röhrich; Kristin Huang; Daniel Schrimpf; Nathalie L Albert; Thomas Hielscher; Andreas von Deimling; Ulrich Schüller; Antonia Dimitrakopoulou-Strauss; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-07       Impact factor: 9.236

3.  Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas.

Authors:  Talia C Oughourlian; Jingwen Yao; Jacob Schlossman; Catalina Raymond; Matthew Ji; Hiroyuki Tatekawa; Noriko Salamon; Whitney B Pope; Johannes Czernin; Phioanh L Nghiemphu; Albert Lai; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2020-01-24       Impact factor: 4.130

4.  The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.

Authors:  Norbert Galldiks; Gabriele Stoffels; Christian Filss; Marion Rapp; Tobias Blau; Caroline Tscherpel; Garry Ceccon; Veronika Dunkl; Martin Weinzierl; Michael Stoffel; Michael Sabel; Gereon R Fink; Nadim J Shah; Karl-Josef Langen
Journal:  Neuro Oncol       Date:  2015-05-24       Impact factor: 12.300

5.  Dual-time-point O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas.

Authors:  Philipp Lohmann; Hans Herzog; Elena Rota Kops; Gabriele Stoffels; Natalie Judov; Christian Filss; Norbert Galldiks; Lutz Tellmann; Carolin Weiss; Michael Sabel; Heinz Hubert Coenen; Nadim Jon Shah; Karl-Josef Langen
Journal:  Eur Radiol       Date:  2015-03-27       Impact factor: 5.315

6.  Influence of Dexamethasone on O-(2-[18F]-Fluoroethyl)-L-Tyrosine Uptake in the Human Brain and Quantification of Tumor Uptake.

Authors:  Carina Stegmayr; Gabriele Stoffels; Elena Rota Kops; Philipp Lohmann; Norbert Galldiks; Nadim J Shah; Bernd Neumaier; Karl-Josef Langen
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488

7.  Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy.

Authors:  Garry Ceccon; Philipp Lohmann; Gabriele Stoffels; Natalie Judov; Christian P Filss; Marion Rapp; Elena Bauer; Christina Hamisch; Maximilian I Ruge; Martin Kocher; Klaus Kuchelmeister; Bernd Sellhaus; Michael Sabel; Gereon R Fink; Nadim J Shah; Karl-Josef Langen; Norbert Galldiks
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

8.  Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.

Authors:  Norbert Galldiks; Marion Rapp; Gabriele Stoffels; Gereon R Fink; Nadim J Shah; Heinz H Coenen; Michael Sabel; Karl-Josef Langen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-29       Impact factor: 9.236

9.  Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase 18F-FET PET accuracy without dynamic scans.

Authors:  Philipp Lohmann; Gabriele Stoffels; Garry Ceccon; Marion Rapp; Michael Sabel; Christian P Filss; Marcel A Kamp; Carina Stegmayr; Bernd Neumaier; Nadim J Shah; Karl-Josef Langen; Norbert Galldiks
Journal:  Eur Radiol       Date:  2016-11-16       Impact factor: 5.315

Review 10.  Brain tumors.

Authors:  Karl Herholz; Karl-Josef Langen; Christiaan Schiepers; James M Mountz
Journal:  Semin Nucl Med       Date:  2012-11       Impact factor: 4.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.